治疗见解:在儿科患者中使用塞夫塔齐迪姆-阿维巴克坦
Özge Metin Akcan1, Mustafa Gençeli1, Talha Üstüntaş2
1Department of Pediatric Infectious Diseases, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.
概括
塞法胺-阿维巴克坦 (CAZ-AVI) 显示出治疗儿童严重多药耐药性细菌感染的前景. 该研究发现,在这个脆弱人群中,微生物根除率高,临床反应具有可接受的安全性.
科学领域:
- 传染性疾病 传染性疾病
- 儿科药理学 儿科药理学
- 抗微生物耐药性 抗微生物耐药性
背景情况:
- 全球越来越多的抗药性 (MDR) 细菌需要新的治疗方法.
- 塞法胺-阿维巴克坦 (CAZ-AVI) 是一种已批准用于特定感染的药物组合.
- 关于CAZ-AVI在儿童群体中的使用的数据有限.
研究的目的:
- 评估CAZ-AVI在患有危及生命的MDR感染的儿科患者的疗效和安全性.
- 在这个特定的患者群体中记录治疗结果和不良事件.
主要方法:
- 一个高等儿童医院的回顾性研究 (2021年12月 - 2023年7月).
- 包括21名患有危及生命的MDR感染的儿科患者.
- 分析了CAZ-AVI单疗法和组合治疗的结果.
主要成果:
- 在85.7% (18/21) 的患者中微生物根除,在95.2% (20/21) 的患者中临床响应.
- 潜在的疾病很常见,包括脑和先天性疾病.
- 副作用包括过敏反应和肌酸酸酶的升高;因胃肠道出血而导致的一例死亡.
结论:
- 在儿童中,CAZ-AVI似乎有望治疗严重的MDR格兰氏阴性感染.
- 需要对更大的队列进行进一步的研究,以确认儿科患者的疗效和安全性.
更多相关视频
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
6.9K
11:20Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos
Published on: May 12, 2020
6.5K
相关概念视频
Combined Effects of Drugs: Synergism
3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.8K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
279
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
279
